http://www.fpnotebook.com/
MeglitinideAka: Repaglinide, Prandin, Nateglinide, Starlix
- See Also
- Second Generation Sulfonylurea
- Mechanism
- Insulin secretogogue
- Indication
- Early Type II Diabetes Mellitus Oral Agent
- Elevated postprandial glucose
- Consider if only used intermittently pre-meal
- Contraindications
- Hypersensitivity Reaction to sulfa
- Category
- Insulin Secretagogue
- Mechanism
- Benzoic acid derivative
- Similar to Sulfonylurea
- Binds different sites from Sulfonylureas
- Closes ATP sensitive K+ channels
- Results in Insulin secretion
- Shorter duration of binding and shorter effect
- Predominately effects postprandial glucose
- Advantages
- Low risk of Hypoglycemia (2.4%)
- Effect depends on Ambient Blood Glucose levels
- No significant gastrointestinal side effects
- Minimal weight gain
- No lab monitoring required
- No significant drug interactions
- No Lactic Acidosis
- No adjustments needed (other than per meal)
- No adjustment in Congestive Heart Failure
- No adjustment for age
- No adjustment in renal insufficiency
- Adverse Effects
- Hypoglycemia (lower risk of Sulfonylureas)
- Disadvantages
- Two to three times as expensive as Sulfonylureas
- Agents
- Repaglinide (Prandin)
- Nateglinide (Starlix)
- Significantly weaker activity compared with Prandin
- References
- Luna (2001) Am Fam Physician 63(9):1747
- Luna (1999) Prim Care 26:895
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | meglitinide |
| Spanish | meglitinida |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Definition (NCI) | A benzoic acid derivative belonging to the meglitinide class of antidiabetic agents. Repaglinide blocks ATP-dependent potassium channels in pancreatic beta cells, thereby causing depolarization of the cell membrane and subsequent opening of calcium channels. The increased calcium influx into the pancreatic beta cells induces insulin secretion, thereby lowering blood glucose levels. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | repaglinide, REPAGLINIDE PREPARATION |
| Spanish | repaglinida |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | Novo Nordisk brand 2 of repaglinide, Prandin |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | IPCCPA, nateglinide, NATEGLINIDE PREPARATION, senaglinide |
| Spanish | nateglinida |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | Novartis brand of nateglinide, Starlix |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree